Exbio — Research products — Antibodies — Other intracellular antigens — Anti-SHIP1 Purified

Anti-SHIP1 Purified

Regulatory status

RUO

Antigen

SHIP1

Clone

SHIP-02

Format

Purified

Reactivity

Human

Application

FC(IC), WB

Variant

0.1 mg

11-525-C100

In stock

165.00 USD

0.025 mg

11-525-C025

Delivery 1 week

82.50 USD

Variant

0.1 mg

11-525-C100

In stock

165.00 USD

0.025 mg

11-525-C025

Delivery 1 week

82.50 USD

Contact distributor

Product details

Description

Images

References

SDS download

Isotype

Mouse IgG2a

Specificity

The antibody SHIP-02 reacts with SHIP-1, a phosphoinositide phosphatase largely confined to hematopoietic cells. Multiple forms of SHIP-1 have been reported with molecular weights of 110, 125, 130, 135 and 145 kDa.

Application

FC(IC), WB

Application details

Flow cytometry: Intracellular staining; recommended dilution: 2-5 μg/ml; positive control: human blood leukocytes.
Western blotting: Positive control: RAMOS human cell line, reducing conditions.

Reactivity

Human

Immunogen

Peptide coresponding to a sequence within N-terminal domain of Human SHIP-1.

Concentration

1 mg/ml

Preparation

Purified by protein-A affinity chromatography.

Formulation

Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide

Storage and handling

Store at 2-8°C. Do not freeze.

The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.

Other names

IPP5PD, IP5PD, INPP5D

Antigen description

SHIP-1 (SH2 domain containing inositol phosphatase-1) is a 5´inositol phosphatase that regulates cell responses in lymphocytes and myeloid cells by hydrolyzing the second messenger PI(3,4,5) trisphosphate. SHIP-1 is recruited upon engagement of both inhibitory and activatory receptors, such as FcgammaRIIB, Fcgamma RIII, FcepsilonRI or cytokine and growth factor receptors, and supresses PI3K-dependent signaling, down-regulates cell migration and invasion of transformed cells and phagocytosis. SHIP-1 also serves as a scaffold for the recruitment of other proteins to the plasma membrane.

Entrez Gene ID 3635

UniProt ID Q92835

Western blotting analysis (reducing conditions) of human SHIP-1 in whole cell lysate of THP-1 human acute monocytic leukemia cell line. Lane 1: immunostaining with Isotype mouse IgG1 control (PPV-04; 11-458-C100) Lane 2,3: immunostaining with anti-human SHIP-1 (SHIP-01; cat. no. 11-524-C100) Lane 4,5: immunostaining with anti-human SHIP-1 (SHIP-02)

Separation of MOLT-4 cells stained using anti-SHIP1 (SHIP-02) purified antibody (concentration in sample 3 μg/ml, GAM APC, red-filled) from MOLT-4 cells unstained by primary antibody (GAM APC, black-dashed) in flow cytometry analysis (intracellular staining).

General references:

Harris SJ, Parry RV, Westwick J, Ward SG: Phosphoinositide lipid phosphatases: natural regulators of phosphoinositide 3-kinase signaling in T lymphocytes. J Biol Chem. 2008 Feb 1;283(5):2465-9.
PubMed

Xing W, Hamaguchi M: Effects of SHIP-1 on MMP2 secretion and invasion of SR3Y1 cells. J Genet Genomics. 2007 Apr;34(4):285-93.
PubMed

Tarasenko T, Kole HK, Chi AW, Mentink-Kane MM, Wynn TA, Bolland S: T cell-specific deletion of the inositol phosphatase SHIP reveals its role in regulating Th1/Th2 and cytotoxic responses. Proc Natl Acad Sci U S A. 2007 Jul 3;104(27):11382-7.
PubMed

Ai J, Maturu A, Johnson W, Wang Y, Marsh CB, Tridandapani S: The inositol phosphatase SHIP-2 down-regulates FcgammaR-mediated phagocytosis in murine macrophages independently of SHIP-1. Blood. 2006 Jan 15;107(2):813-20.
PubMed